Compare Quest Diagnostics Inc (DGX) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Consolidated Edison, Inc. — how do they compare? Quest Diagnostics Inc trades at $231.12 (market cap $25.48B), while Consolidated Edison, Inc. trades at $105.62 (market cap $39.20B). The key difference: Consolidated Edison, Inc. is the larger of the two by market cap, and Consolidated Edison, Inc. pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Consolidated Edison, Inc. for 75 Days on average.
| DGX | ED | |
|---|---|---|
Market Cap | $25.48B | $39.20B |
Volume | 941,866 | 2,142,900 |
Sector | Health | Utilities |
52-Week High | $247.45 | $115.46 |
52-Week Low | $173.49 | $95.37 |
Typical Hold Time | 56 Days | 75 Days |
Enterprise Value | $31.23B | $66.05B |
Dividend Yield | 1.49% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Consolidated Edison (ED) trades at $104.65, down 0.45% on the day, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The company maintains solid fundamentals with a P/E of 17.43, net income margin of 12.53%, and a $0.89 dividend. Revenue grew to $16.92B in 2025, with cash flow from operations strong at $4.80B. Analyst consensus is a Hold with a $106.33 price target, slightly above the current price.
ED's outlook is stable, supported by its utility business model and dividend aristocrat status, but faces risks from high debt levels and interest expenses. The stock offers income appeal with moderate growth potential, though investor sentiment is cautious amid mixed analyst ratings and institutional selling trends noted in recent filings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
